Indeed, initial case reports indicate an antitumor activity of PDE5 inhibition in patients with Waldenstrom's macroglobulinemia (61), B-cell chronic lymphocytic leukemia (62), and penile cancer (63). Here, PDE5A is linked to Waldenstrom macroglobulinemia.